WBMP-4IgM-expressing B-cell malignanciesWelt Bio-Molecular Pharmaceutical
…hibition and ADCC to be achieved by one modality. Our lead mAb, WBMP-4, binds to membrane-bound IgM, within the B-cell Receptor (BCR),…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 398 of 2459squamous cell carcinomaHNSCCintra-tumoral immunotherapy injectionpulsed electrical field ablationInt J Mol Scihepatocellular carcinoma
…ss B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. Nov 26 2020;6(1):92.Chen SMY, Krinsky AL,…
nivolumabMucosal melanomaipilimumabInova Schar Cancer Instituterelatlimablocally advanced mucosal melanoma
…t-remission, one of whom achieved CR after salvage therapy with nivolumab. Among the 4 patients who were treated with relatlimab and nivo…
durvalumabbevacizumabtremelimumabhepatocellular carcinomaunresectable hepatocellular carcinomaHCCJ Clin Oncol
…im T-Y, Tai WMD, Kang Y-K, Lau G, et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: resu…
Lung cancerNivolumabIpilimumabNSCLC
…Background Lung cancer is the leading cause of cancer-related deaths worldwide, and no…
Flotillin-2Flot2Flot2-silencedFlot2-deficient
…ce Moon S, Zhao F, Uddin MN, Tucker CJ, Karmaus PW, Fessler MB. Flotillin-2 dampens T cell antigen sensitivity and functionality. JCI Insig…
head and neck squamous cell carcinomaRenal cell carcinomanon-small cell lung cancerimmunotherapyProvidence St. Joseph Health Institutional Review Board – Oregonimmunotherapy-refractoryRCC
…cell-cell interactions among a cohort of primary breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, and RCC specimens. Putative tumor …
GlioblastomaGBM89Zr-DFO-anti-Ly6G89Zr
…Background Glioblastoma (GBM) is the most common and lethal primary malignant brain tum…
Pancreatic cancerChloroauratePembrolizumabAurothiomalatePDACAM
…Background Pancreatic cancer is traditionally considered an ‘immune cold’ tumor. Although ou…
bladder cancerThe University of North Carolina at Chapel Hillanti-PD-1 therapyimmune checkpoint inhibitorsICIICI therapy
…Background The use of immunologic agents to treat bladder cancer has been beneficial in both muscle-invasive and non-muscle inva…
NSCLCLewis lung carcinomaadvanced non-small cell lung cancer
…T cells (Tregs; 8.09% vs. 4.18%, P < 0.05) in anti-PD-1-treated NSCLC patients compared to untreated controls. These findings implica…
The Ohio State University Comprehensive Cancer CenterMerkel cell carcinomaOSUCCCPelotonia Institute for Immuno-OncologyMCCNational Institutes of HealthNIHanti-PD-1/PD-L1 therapies
…wledgements Research reported in this Abstarct was supported by The Ohio State University Comprehensive Cancer Center (OSUCCC) and the National Institutes of Health (NIH) under gran…